921 related items for PubMed ID: 19279320
1. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
[Abstract] [Full Text] [Related]
2. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 09; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
3. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR, Cadavid D, Wolansky L, Skurnick J.
Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
[Abstract] [Full Text] [Related]
4. Seeing injectable MS therapies differently: they are more similar than different.
Fox RJ, Arnold DL.
Neurology; 2009 Jun 09; 72(23):1972-3. PubMed ID: 19439722
[No Abstract] [Full Text] [Related]
5. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
Neurol Sci; 2005 Dec 09; 26 Suppl 4():S174-8. PubMed ID: 16388353
[Abstract] [Full Text] [Related]
6. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G, Filippi M, Wolinsky JS.
Ann Neurol; 2001 Mar 09; 49(3):290-7. PubMed ID: 11261502
[Abstract] [Full Text] [Related]
7. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
Acta Neurol Scand; 2006 Jun 09; 113(6):378-86. PubMed ID: 16674604
[Abstract] [Full Text] [Related]
8. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW, Stephen R, Seaman C, Rajagopalan K.
Curr Med Res Opin; 2010 Mar 09; 26(3):663-74. PubMed ID: 20070144
[Abstract] [Full Text] [Related]
9. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
[Abstract] [Full Text] [Related]
10. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
[Abstract] [Full Text] [Related]
11. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
[Abstract] [Full Text] [Related]
12. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC.
J Neurol Sci; 2004 Aug 15; 223(1):69-71. PubMed ID: 15261564
[Abstract] [Full Text] [Related]
13. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
14. Lessons from randomised direct comparative trials.
Achiron A, Fredrikson S.
J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S19-24. PubMed ID: 19200860
[Abstract] [Full Text] [Related]
15. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 01; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
Lancet Neurol; 2008 Oct 01; 7(10):903-14. PubMed ID: 18789766
[Abstract] [Full Text] [Related]
17. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
Waubant E, Sloan R, Andersson PB, Goodkin D.
Rev Neurol (Paris); 1999 Oct 01; 155 Suppl 2():S20-3. PubMed ID: 10367321
[Abstract] [Full Text] [Related]
18. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
Ann Neurol; 2004 Oct 01; 56(4):548-55. PubMed ID: 15389896
[Abstract] [Full Text] [Related]
19. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
20. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
